Introduction
Prevention of meningeal relapse is crucial for all children with acute lymphoblastic leukemia (ALL), as the central nervous system (CNS) is a known sanctuary for lymphoblasts. Initial CNS involvement is found in 3-5% of patients. [1] [2] [3] [4] However, majority of ALL patients have occult CNS involvement 5 and the prognosis of CNS relapses is still unsatisfactory, although recent improvement has been reported with event free survival up to 70%. [6] [7] [8] CNS prophylaxis is currently based on intrathecal chemotherapy (IT) with MTX7steroid and cytarabine (Cyt) and prophylactic cerebral irradiation indicated for children with ALL with a HR of CNS relapse. The incidence of CNS relapse is currently between 1.5 and 5% depending on the study. 9 Neurotoxicity during treatment have been reported since 1970. The principal drugs incriminated are vincristine, methotrexate (MTX), Cyt and asparaginase. 2, 10, 11 Vincristine mainly causes peripheral neuropathies, ranging from abolition of the Achille's reflex and paresthesias of the extremities to distal motor impairment. These neuropathies are dose-dependent and usually reversible. High-dose intravenous and intrathecal (i.t.) Cyt can cause syndrome combining seizures, encephalopathy, cerebella involvement and myelitis. [12] [13] [14] Intrathecal (i.t.) MTX and high-dose methotrexate (HD MTX) can induce seizures, polyradiculoneuritis, myelitis, transient neurological deficits and multifocal encephalopathy. Asparaginase can contribute to this neurotoxicity by modifying hemostasis, with an increased risk of cerebral thrombosis during treatment. 14, 15 The exact incidence of these complications is difficult to determine, as most data come from isolated case reports. [15] [16] [17] [18] [19] [20] Similarly, the outcome of children with acute neurotoxicity is poorly documented. Yet improvements in outcome in recent years have placed the accent on prevention of treatment sequels. We therefore analyzed acute neurotoxicity occurring during the multicenter trial FRALLE 93, conducted between 1993 and 1999, in order to determine their frequency and type, to identify possible risk factors and to determine the impact of this toxicity on overall outcome.
Patients and methods
Between 1993 and 1999, 1395 children with ALL (778 boys, 617 girls) were enrolled in the FRALLE 93 study. Informed consent was obtained from all patients' parents in accordance with national ethic rules. Median age was 5.2 years (1, (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . ALL was of the B lineage in 1195 cases (86%) and T cell in 200 cases (14%). The low-, intermediate-and high-risk (LR, IR and HR) groups comprised respectively 182 (13%), 672 (48%) and 541 (39%) children. Main clinical characteristics are resumed on Table 1 .
Acute neurological events were initially reported to the coordinating investigators of the FRALLE 93 study. Following the creation of a neurotoxicity task force, a standard questionnaire was subsequently addressed to each participating center and completed by the physician responsible for the child at the time of the event.
The following information concerning each event was recorded: clinical manifestations, treatment group, treatment phase, number of IT and HD MTX courses received, MTX elimination, time since last IT, CSF abnormalities, radiological and neurophysiologic findings, protocol modifications, sequel and final status (up to July 2005). Neurotoxicity was defined according to the criteria of the World Health Organization (WHO) classification. Only grade 3-4 events are reported. Peripheral neuropathies unequivocally owing to vincristine (isolated sensory toxicity or moderate gait disorders) were not included in the study.
Treatment
The FRALLE 93 study population was stratified into three groups (LR, IR and HR) based on the following risk factors: age, white cell count at diagnosis, hemoglobin level, immunophenotype, karyotype and steroid response. Low-risk group was defined by: age o7 and over 1 year, white cell count o10.10 9 /l, B lineage c-ALL CD 10 positive and no adverse cytogenetics findings. HR group was defined by at least one major criteria : age 415 years or below 1 year, white cell 4100.10 9 /l, t(9;22) or t(4,11) or hypoploid or tetraploid caryotype, T-cell lineage or at least 2 minor criteria: age 410 years, tumor syndrome, Hb410 G/l, white cell count 450.10 9 /l, two myeloid antigens expression such as CD13, CD33 or CD14. Intermediate group was defined by exclusion of two others groups. Treatment design is resumed in Figures 1 and 2 . HR patients received one of the following three treatment groups: group C1, steroid good responders: chemotherapy with two intensifications; group C2, very HR patients steroid-resistant on D8 or M2 or M3 bone marrow at day 21: intensification with six cycles of chemotherapy, followed by autografting; group C3, allogenic bone marrow transplantation (BMT) in case of HLA-matched sibling donor. Allogenic BMT was indicated for all patients with t (9;22) or t (4;11) or hypoploid caryotype. 
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Statistical analysis
Distribution of qualitative variables was compared with the twosided Fisher's exact test and w 2 test. Considering the number of neurological events in each group, multivariate analysis was not performed. The Kaplan-Meier method was used to evaluate disease-free survival probabilities and relapse risks. Comparisons of two Kaplan-Meier curves were made using the log-rank test. In all analyses, the limit of significance was assigned as Pp0.05.
Results
Fifty-two children (3.7%) had grade 3-4 acute neurotoxicity. Their main characteristics are shown in Table 2 and Figure 3 .
Three types of neurological symptoms were observed, peripheral and spinal neuropathy n ¼ 17 (33%), isolated seizures n ¼ 15 (29%) and encephalopathy n ¼ 20 (38%). Eleven (21%) of the 52 children relapsed and seven (13.5%) died. Overall survival of the 52 patients is 86%79 with a median follow-up of 102 months.
Seizures (n ¼ 15)
Fifteen patients had seizures; focal signs were seen in four cases (Table 3) . Three patients presented subsequent seizures after 48 h. Ten out of 15 had clinical signs of acute arachnoiditis. In four cases, imaging studies at the end of treatment showed signal abnormalities of the white matter, compatible with MTX toxicity.
Six cases occurred during induction, four during consolidation, one during the interphase, two during intensification and two during maintenance therapy. The patients had received a median of three TIT (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , and the seizures occurred a median of 8 days after the last injection.
CT showed abnormalities in 4/14 documented cases. Two patients presented thrombosis after the sixth Asparaginase injection during induction. Both presented further risk factors for thrombosis: oral contraception and partial protein S deficiency in one case and oral contraception and familial hypertriglyceridemia in the other case. Two patients (patients 15 and 9) had imaging signs of ischemic stroke. In patient 15, the seizures occurred during the maintenance phase with LD MTX, 3 months after TIT. CT was normal but magnetic resonance imaging (MRI) showed a focal white matter hyposignal. In patient 9, seizures occurred 8 days after the first intensive consolidation cycle with HD MTX COPADM (T-cell ALL with CNS involvement), CT after the seizures showed bilateral parietal hypodensities; MRI showed CSF infiltration. Seven children had CT, three had both normal CT and MRI but angiographic-MRI was not performed in any cases. In only one case (patient 12), the child was febrile at seizure onset and blood culture yielded Staphylococci epidermidis. Most children had no treatment modifications. Fourteen children (14/15) received the entire course of CNS prophylaxis; TIT were delayed in one case and one child received IT without Cyt. Six children received antiepileptic therapy. None have functional sequels but cognitive evaluation was not performed. To summarize, out of 15 seizures, two were asparaginase-related, six methotrexaterelated, one link to CNS leukemia and the other six possibly to vincristine, IT or individual suceptibility but without optimal imaging investigations.
Peripheral and spinal neuropathy (n ¼ 17)
Clinical manifestations were of three principal types: (Table 4) .
Spinal involvement (seven patients, [16] [17] [18] [19] [20] [21] [22] : Two patients had flaccid quadriplegia with sensory and sphincter disorders. The other five patients had solely motor involvement; paraplegia was accompanied in three cases by pyramidal signs (Babinski sign, brisk osteo-tendinous reflexes). Spinal MRI was abnormal in 4/7 children, with peri-spinal contrast enhancement in three cases and epidural enhancement in two cases (both abnormalities in one patient); Anterior horn involvement (three patients, [23] [24] [25] : rapidly progressive purely motor neuropathy (flaccid paraplegia) with lesions of the anterior horn on nerve conduction study (NCS) and electromyography (EMG). MRI was normal in every case; Peripheral involvement (five patients, 26-30): Sensory-motor radiculoneuritis and elevated proteinorachia (2/5); one child had CSF hypercellularity; EMG and NCS showed axonal lesions. MRI was always normal. Data were missing for two of these 17 children because they were lost of follow-up. One case occurred during induction, two during consolidation, seven during intensification and five during maintenance therapy. The median TIT number was 10 (2-18), and onset occurred a median of 13 days after the last injection.
Six of the 15 children fully recovered but nine have chronic sequels and recovered very slowly. Spinal involvement had the worst functional prognosis. After an average follow-up of two years, physical examination of eight of these nine children showed: persistent paraplegia and need for urinary drainage (n ¼ 1, patient 16); walking possible with canes þ plastered splints, urination by abdominal pushing (n ¼ 1, patient 20); walking with corrective splints for varus equinus (n ¼ 2);
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Encephalopathy (n ¼ 20)
Encephalopathy occurred in 20 children (six girls, 14 boys and median age 7.9 years, range 2.4-14.7 years) (Table 5a, b). Two LR patients (2/2) and 10/12 IR patients were randomized to receive HD MTX. The manifestations were polymorphous, with ; CT, computed tomography; delay IT (dy), day number between last IT and seizure; HD MTX, high-dose methotrexate; HR, high risk; IR, intermediate risk; IT, intrathecal chemotherapy; IT nb, IT number before seizure; LR, low risk; MRI, magnetic resonance imaging; ND, no data; NP, not performed; P (g/l), proteinorachia in g/l. aphasia, hemiplegia, VI, VII, III paralysis, spasmodic laughing and crying, ataxia and coma. The symptoms resolved within 48 h in 12/20 children (1/2-48 h). Sixteen cases occurred during consolidation, three during intensification and one during maintenance therapy with median TIT number of 6 (3-14) and median of 9 days after the last IT injection (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Imaging studies were abnormal in 12/17 documented cases, showing mainly signs of leukoencephalopathy (10 cases) associated with ischemia features in three cases, hemorrhage in two cases and thrombosis in one case. Four had both normal CT and MRI, one had normal CT but no MRI performed and three had no imaging studies. A clotting disorder (factor V Leiden heterozygote) was found in patient 35. Finally, interferon was detected in the CSF of 1/1 patient (patient 39). Seven/out of 20 children (33%) have a neurological deficit and require rehabilitation. We found no predictors of neurological recovery except initial duration symptoms (oor 448 h). Treatment was modified in 12/20 cases: cessation of TIT (n ¼ 4), IT without MTX (n ¼ 2), IT without Cyt (n ¼ 1), HD MTX or asparaginase withdrawal (n ¼ 4) and vincristine dose reduction (n ¼ 1). HD MTX and TIT were replaced by 18 Gy CNS radiotherapy (n ¼ 1).
Statistical analysis
Analysis of risk factors for neurological complications during treatment are summarized in Tables 6-9 .
Comparing the neurological complications group to the whole population of patients, age 410 years is associated with higher risk of neurotoxicity (P ¼ 0.01). When comparing each subgroup to the whole population of patients without neurotoxicity, age 410 years is either associated with higher risk of neurotoxicity in encephalopathy (P ¼ 0.02) and seizures (P ¼ 0.03) subgroups but not in the spinal subgroup (P ¼ 0.61). We found no association with leukemia type or initial CNS leukemia (P ¼ 0.07), although a very small number of patients presented seizure and CNS leukemia.
When-focusing on methotrexate in subsequent neurotoxicity, HD MTX is highly significantly correlated to encephalopathy (P ¼ 0.03).
Event-free survival (EFS) and overall survival (OS) in subgroups with or without neurological complications are without any significance (P ¼ 0.15 and P ¼ 0.36 respectively).
Discussion
The global incidence of neurological complications of leukemia therapy in children is difficult to appreciate owing to the small number of published series and their heterogeneity. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Moreover, under description owing to insufficient means for monitoring is possible. When limited to grade 3-4 episodes, the neurological complications incidence in our series is 3.7%.
In the largest series reported to date, Mahoney et al. 27 found an overall incidence of 7.8% (95/1218) in low-risk ALL, seizures representing 78/95 events. The authors attributed this acute toxicity to HD MTX combined with IT MTX with non adapted folinic acid rescue (25 vs 69 mg/m 2 in previous studies). ) plus TIT. 30 The highest incidence (19% of 138 patients) was reported by Winick et al., 23 with seizures (17/25), followed by transient hemiparesis (6/25) and episodes of disorientation and irritability (2/25). Most incidents occurred 10 days after concurrent systemic and intrathecal Cyt administration. IT Cyt was subsequently removed, but the incidence of neurotoxicity only fell when rescue therapy was introduced. The authors concluded that folinic acid probably modulated MTX toxicity and interactions with other drugs such as Cyt.
In our study, HD MTX administration was associated with a significant risk of encephalopathy (P ¼ 0,03). Pathogenesis of neurotoxicity related to methotrexate remains unclear. [31] [32] [33] It has been suggested that MTX induces hyperhomocysteinemia, a risk factor for vascular disease and thrombosis. Focal deficit, microangiopathy and white matter lesions observed with MTX argue for vascular pathogenesis. Moreover, CSF and plasma homocysteine concentration were found significantly greater in patients with neurotoxicity after HD MTX treatment. 34 But no significant differences in plasma or CSF homocysteine levels were found based on the five, 10-methylenetetrahydrofolate reductase genotypes. 35 In the Rubnitz et al. 28 study, 8/259 patients experienced methotrexate-induced transient encephalopathy (o3 days) with normal MRI in 7/8 cases and leukoencephalopathy in 1/8 case. Interestingly, age greater than equal to 10 years at diagnosis was associated with the development of transient encephalopathy.
There is no consensus on the management of neurotoxicity in this setting. If symptoms persist, it seems unreasonable to continue HD MTX. In contrast, transient acute encephalopathy does not seem to contraindicate MTX resumption. 28, 36 The incidence of spinal and peripheral neurotoxicity in our study was 1.2%, a figure compatible with the literature. In this group the number median of IT injections was 10, compared to six in patients with encephalopathy and three in patients with seizures, pointing to the possible role of cumulative toxicity. The prognosis was poor, 66% have severe functional sequels. The gravity of the initial paresis and a lack of recovery during first three months have previously been linked to a bad prognosis. 37 The mortality rate was lower than in the literature. 38 Five children had symptoms of polyradiculoneuritis. The mechanism is probably different, and the prognosis is better. Cyt is possibly involved in spinal toxicity, although few relevant complications have been reported. In 1992, Resar 14 report a case of myelopathy and a case of encephalopathy after IT Cyt (50 mg/m 2 on three consecutive days). Furthermore, the review of 12 other cases of the literature does not allow firm conclusions concerning cumulative compared with a dose-toxic threshold with Cyt. 39 In the study by Watterson et al., 40 on 23 patients with hematologic malignancies (n ¼ 17), or solid tumors (n ¼ 6) receiving an intensive CNS prophylactic (13 had CNS involvement), three received only Cyt IT before developing myelopathy. Pui et al. 41 have shown that therapeutic escalation by TIT in ALL significantly reduces the risk of CSF relapse (165 patients, estimated risk 1.2%). However, Matloub et al. 42 showed that, although the number of CNS relapses was lower in the TIT group relative to the group treated with simple MTX IT, EFS was similar because of more frequent bone marrow relapses in the TIT group.
In our series, three children (0.2%) had thrombosis during administration of Asparaginase. 43, 44 In the literature, sinovenous thrombosis prevalence of 0, 47% was found in a group of 2318 children with ALL. 45 The frequency of this complication is probably underestimated as brain CT can initially be normal and vascular MRI not always performed. 46, 47 As vascular MRI allows better definition of cerebral tissues such exam has to be recommended. Thrombosis are currently under review in the FRALLE protocols.
In conclusion, we found a significant link between encephalopathy and HD MTX in the FRALLE 93 protocol. Although evaluation has been retrospective and therefore lead to some interpretation bias, this raises the question of how to identify patients at risk of such neurotoxicity. The only prognostic factor identified here was age which was significantly higher in patients with neurological complications. Further studies are necessary to evaluate the predictive value of biological assays for neurological events linked to MTX.
Rare but severe peripheral and spinal neuropathies apparently related to intrathecal injections raise the question of TIT indications.
Isolated seizures are not accompanied by particular sequel and do not justify long-term anticonvulsant therapy. They can, however, reveal cerebral thrombosis. And finally, the onset of severe neurological toxicity during treatment of childhood ALL did not significantly compromise OS or EFS in our study. Detailed monitoring and report of neurological toxicity in further trials is essential.
